Mounjaro and Crohn's Disease: Safety & UK Guide

Clinically Proven UK Registered Pharmacy

Mounjaro and Crohn's Disease - From £124.99

Cheapest UK price from £124.99 with £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro and Crohn's Disease: Safety, Contraindications, and Clinical Guidance

Published: 10 September 2026

Mounjaro and Crohn's disease is a critical consideration for patients and prescribers, as tirzepatide's gastrointestinal effects may interact with inflammatory bowel conditions. While Mounjaro is licensed in the UK for weight management in eligible adults, individuals with active or poorly controlled Crohn's disease require careful clinical assessment before treatment initiation. This guide provides evidence-based insights into safety, contraindications, and prescribing considerations for patients with Crohn's disease seeking Mounjaro therapy.

Understanding Mounjaro and Crohn's Disease: Key Considerations

Mounjaro and Crohn's disease require careful evaluation because tirzepatide acts on GLP-1 and GIP receptors, which influence gastrointestinal motility, gastric emptying, and intestinal secretion[1]. Crohn's disease is a chronic inflammatory bowel condition characterised by transmural inflammation, abdominal pain, diarrhoea, and malabsorption. Patients with active Crohn's disease often experience gastrointestinal symptoms that may overlap with or be exacerbated by Mounjaro's known side effects, including nausea, vomiting, diarrhoea, and abdominal discomfort.

Clinical trials for tirzepatide (SURPASS-1 to SURPASS-5) excluded patients with active inflammatory bowel disease, meaning there is limited direct evidence on safety and efficacy in this population[2]. UK prescribers must therefore assess each patient individually, considering disease activity, current medications (such as immunosuppressants or biologics), nutritional status, and risk of dehydration or malabsorption. Mounjaro is not contraindicated solely based on a Crohn's diagnosis, but active disease or recent flare-ups warrant caution and specialist input.

Mounjaro and Crohn's Disease: Gastrointestinal Side Effects and Risk Management

Mounjaro and Crohn's disease management must account for the medication's gastrointestinal tolerability profile. In clinical trials, nausea (12–22% of patients), diarrhoea (13–16%), vomiting (6–9%), and abdominal pain (6–9%) were commonly reported, particularly during dose escalation[1]. For patients with Crohn's disease, these side effects may mimic or worsen disease symptoms, making it difficult to distinguish treatment-related adverse events from disease flare-ups.

UK prescribers should ensure patients with Crohn's disease are in remission or have well-controlled symptoms before initiating Mounjaro. Baseline inflammatory markers (C-reactive protein, faecal calprotectin) and recent endoscopic or imaging findings help inform decision-making. Patients should be counselled on the importance of adequate hydration, gradual dose titration, and prompt reporting of severe or persistent gastrointestinal symptoms. Those on immunosuppressive therapy or biologics (such as infliximab or adalimumab) require monitoring for drug interactions and infection risk, though no direct pharmacokinetic interactions between tirzepatide and these agents have been documented[3].

Dehydration and Nutritional Concerns in Crohn's Patients

Patients with Crohn's disease are at higher risk of dehydration and electrolyte imbalance, particularly if they have active diarrhoea or stricturing disease. Mounjaro's gastrointestinal side effects can compound this risk, especially during the first 4–8 weeks of treatment. UK clinical guidance recommends close monitoring of fluid intake, weight, and signs of dehydration (dizziness, reduced urine output, dry mucous membranes) in patients with inflammatory bowel disease. Nutritional status should also be assessed, as malabsorption or reduced oral intake may affect tolerability and weight loss outcomes.

Mounjaro and Crohn's Disease: Contraindications and Prescribing Caution

Mounjaro and Crohn's disease are not an absolute contraindication, but certain clinical scenarios require prescriber caution or exclusion. Active gastrointestinal obstruction, severe malnutrition, or recent bowel surgery are relative contraindications to tirzepatide therapy. Patients with a history of gastroparesis or severe gastroesophageal reflux disease (GERD) should also be assessed carefully, as delayed gastric emptying induced by Mounjaro may worsen these conditions[1].

UK prescribers must also consider the patient's overall treatment goals and disease trajectory. If Crohn's disease is poorly controlled or the patient is undergoing frequent flare-ups, optimising inflammatory bowel disease management should take priority over weight loss therapy. Mounjaro is licensed for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, subject to clinical assessment by a UK-registered prescriber. Patients with Crohn's disease who meet these criteria and have stable disease may be suitable candidates, provided they are closely monitored throughout treatment.

Specialist Referral and Multidisciplinary Care

For patients with complex Crohn's disease or those on multiple immunosuppressive agents, a multidisciplinary approach involving gastroenterologists, dietitians, and specialist pharmacists is recommended. UK guidelines emphasise shared decision-making, ensuring patients understand the potential risks and benefits of Mounjaro therapy in the context of their inflammatory bowel disease. Specialist input may also be required if patients develop new or worsening gastrointestinal symptoms during treatment, to differentiate between drug side effects and disease progression.

Treatment Type Frequency Starting Price
Mounjaro (Tirzepatide) GLP-1/GIP agonist injection Once weekly £145.00
Wegovy (Semaglutide) GLP-1 agonist injection Once weekly £89.00
Wegovy Oral Tablets GLP-1 agonist pill Once daily £83.00
Saxenda (Liraglutide) GLP-1 agonist injection Once daily £68.00
Orlistat Lipase inhibitor capsule Three times daily £32.00

Mounjaro and Crohn's Disease: Clinical Evidence and Real-World Experience

Mounjaro and Crohn's disease have not been studied in dedicated clinical trials, as patients with active inflammatory bowel disease were excluded from the SURPASS programme[2]. However, post-marketing surveillance and real-world data are beginning to emerge, providing insights into tolerability and safety in this population. UK pharmacovigilance data and case reports suggest that patients with well-controlled Crohn's disease generally tolerate tirzepatide, though gastrointestinal side effects may be more pronounced or prolonged compared to the general population.

Prescribers should counsel patients on the importance of distinguishing between expected side effects (which typically improve after 4–8 weeks) and signs of Crohn's flare-up (such as bloody stools, fever, severe abdominal pain, or weight loss exceeding expected treatment effects). Regular follow-up appointments, including assessment of inflammatory markers and symptom diaries, help ensure safe and effective use of Mounjaro in patients with Crohn's disease[4].

Mounjaro and Crohn's Disease: Dosing, Titration, and Monitoring

Mounjaro and Crohn's disease patients should follow the standard dosing schedule unless otherwise directed by their prescriber. Treatment begins with a 2.5 mg subcutaneous injection once weekly for four weeks, followed by an increase to 5 mg weekly. Doses may be escalated every four weeks (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) based on tolerability and weight loss response[1]. For patients with Crohn's disease, slower titration may be warranted to minimise gastrointestinal side effects and allow time to assess disease stability.

UK prescribers should arrange baseline and follow-up assessments at 4, 8, and 12 weeks, with additional monitoring as needed. Parameters to track include weight, BMI, gastrointestinal symptoms, hydration status, and inflammatory markers. Patients should be advised to inject Mounjaro into the abdomen, thigh, or upper arm, rotating injection sites to reduce local reactions. Those on concurrent medications for Crohn's disease (such as mesalazine, azathioprine, or biologics) should be monitored for any changes in disease control or medication efficacy, though no direct drug interactions are expected.

When to Discontinue or Adjust Treatment

Mounjaro should be discontinued if patients with Crohn's disease develop severe or persistent gastrointestinal symptoms that do not improve with dose reduction, if there is evidence of disease flare-up requiring escalation of Crohn's therapy, or if dehydration or malnutrition occurs. UK clinical guidance recommends stopping tirzepatide if weight loss goals are not achieved after 16 weeks at the maximum tolerated dose, or if adverse effects outweigh clinical benefits. Patients should never adjust or stop Mounjaro without consulting their prescriber, as abrupt discontinuation may lead to weight regain or metabolic changes.

Mounjaro and Crohn's Disease: Accessing Treatment at Cured Pharmacy

Mounjaro and Crohn's disease patients can access tirzepatide therapy at Cured Pharmacy from £124.99, subject to clinical assessment by a UK-registered prescriber. Our online consultation process takes under three minutes and includes a comprehensive review of your medical history, current medications, and Crohn's disease status. All prescriptions are issued by GMC-registered clinicians and dispensed by our GPhC-registered pharmacy (Superintendent Pharmacist: Tarun Kumar, GPhC 2233073), ensuring safe, legal, and discreet delivery to your door.

Patients with Crohn's disease will be asked specific questions about disease activity, recent flare-ups, current treatments, and gastrointestinal symptoms during the consultation. In some cases, additional information from your gastroenterologist or GP may be requested to ensure Mounjaro is appropriate for you. Cured Pharmacy offers transparent upfront pricing, 100% discreet packaging, and ongoing clinical support throughout your treatment journey. First-time customers can Save £20 off their first order with code Weightlossnew, making Mounjaro accessible from £124.99[5].

Scientific References

  1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. [accessed 10 September 2026]
  2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. [accessed 10 September 2026]
  3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. [accessed 10 September 2026]
  4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. [accessed 10 September 2026]
  5. Cured Pharmacy. (2025). Mounjaro Weight Loss Injections (Tirzepatide) KwikPen. Cured Pharmacy. [accessed 10 September 2026]
  6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
  7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
  8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Is Mounjaro safe for people with Crohn's disease?
Mounjaro and Crohn's disease require individual assessment by a UK prescriber. Patients with well-controlled Crohn's may be suitable candidates, but active disease or severe symptoms warrant caution due to overlapping gastrointestinal side effects.
Can Mounjaro cause a Crohn's disease flare-up?
There is no evidence that Mounjaro directly triggers Crohn's flare-ups, but its gastrointestinal side effects (nausea, diarrhoea, abdominal pain) may mimic or worsen symptoms. Close monitoring is essential to distinguish between drug effects and disease activity.
Should I stop my Crohn's medication before starting Mounjaro?
No. Mounjaro and Crohn's disease medications (such as mesalazine, azathioprine, or biologics) can generally be taken together, with no known direct interactions. Always consult your prescriber before making any changes to your treatment regimen.
How do I know if my symptoms are from Mounjaro or my Crohn's disease?
Mounjaro-related side effects typically peak during dose escalation and improve over 4–8 weeks, while Crohn's flare-ups may include bloody stools, fever, or severe pain. Contact your prescriber if you experience persistent or worsening symptoms.
Can I use Mounjaro if I have had bowel surgery for Crohn's disease?
Mounjaro and Crohn's disease patients with a history of bowel resection or surgery should be assessed individually. Recent surgery or active complications (such as strictures or fistulas) may be contraindications to tirzepatide therapy.
Will Mounjaro affect my Crohn's disease blood tests?
Mounjaro does not directly alter inflammatory markers such as C-reactive protein or faecal calprotectin. However, weight loss and improved metabolic health may indirectly influence some laboratory results. Your prescriber will monitor relevant parameters throughout treatment.
How much does Mounjaro cost at Cured Pharmacy for Crohn's patients?
Mounjaro is available from £124.99 at Cured Pharmacy, with £20 off your first order using code Weightlossnew. All patients, including those with Crohn's disease, require a clinical assessment by a UK-registered prescriber before treatment can be issued.
What should I do if I develop severe diarrhoea on Mounjaro with Crohn's disease?
Severe or persistent diarrhoea in patients with Crohn's disease on Mounjaro requires urgent medical review to assess for dehydration, electrolyte imbalance, or disease flare-up. Contact your prescriber immediately and ensure adequate fluid intake.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 10 September 2026

Last updated on 10 September 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 10 September 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (10 September 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.